Trial Profile
An Observational, Prospective Safety Study in Subjects With Type 2 Diabetes Mellitus Starting NovoMix 30 (Biphasic Insulin Aspart) Treatment.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Nov 2016
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 16 Oct 2009 Actual patient number changed from 515 to 509 as reported by ClinicalTrials.gov.
- 16 Sep 2009 Actual initiation date changed from Apr 2008 to Sep 2008 as reported by ClinicalTrials.gov.
- 11 Jul 2008 New trial record.